|Mr. Shaun Edward Chilton||CEO & Exec. Director||1.55M||N/A||1968|
|Mr. Nicholas P. Keher||CFO & Exec. Director||774.15k||N/A||N/A|
|Mr. Sam Herbert||Chief Operating Officer||N/A||N/A||N/A|
|Matt Parrish||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Amanda Miller||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Mr. David Bryant||Director of Corp. Devel.||N/A||N/A||N/A|
|Jessica Archer||Global HR Director||N/A||N/A||N/A|
|Mr. Mark Corbett||Managing Director of Global Access Division||N/A||N/A||N/A|
|Mr. Johannes Willemse||Chief Commercial Officer||N/A||N/A||1968|
|Mr. Ivo Timmermans M.D., MBA||Chief Medial Officer||N/A||N/A||1960|
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Clinigen Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.